Novavax (0A3S) Share Forecast & Price Target

Compare

16 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0A3S Analyst Ratings

Hold

2 Buy

1 Hold

1 Sell

Based on 4 analysts giving stock ratings to

Novavax

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0A3S Stock 12 Month Forecast

Average Price Target

$11.00

▲(26.00% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is $11.00 with a high forecast of $19.00 and a low forecast of $7.00. The average price target represents a 26.00% change from the last price of $8.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","8.75":"$8.75","12.5":"$12.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.75,12.5,16.25,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,8.44,9.32,10.2,11.08,11.96,12.84,13.72,14.600000000000001,15.48,16.36,17.240000000000002,18.12,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,7.8246153846153845,8.089230769230769,8.353846153846153,8.618461538461538,8.883076923076922,9.147692307692306,9.412307692307692,9.676923076923076,9.94153846153846,10.206153846153846,10.47076923076923,10.735384615384614,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.56,7.516923076923076,7.473846153846154,7.43076923076923,7.387692307692308,7.344615384615384,7.3015384615384615,7.258461538461538,7.2153846153846155,7.172307692307692,7.1292307692307695,7.086153846153846,7.043076923076923,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.118,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.498,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.741,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.881,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.581,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.085,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.938,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.625,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.528,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$19.00

Average Price Target$11.00

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thomas Shrader

BTIG

$19

Buy

117.64%

Upside

Reiterated

09/02/25

Optimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy Rating

Sean Lee CFA

H.C. Wainwright

$10

Buy

14.55%

Upside

Initiated

08/28/25

Novavax assumed with a Buy at H.C. WainwrightNovavax assumed with a Buy at H.C. Wainwright

Alec Stranahan

Bank of America Securities

$9→$7

Sell

-19.82%

Downside

Downgraded

08/20/25

Novavax downgraded to Underperform from Neutral at BofANovavax downgraded to Underperform from Neutral at BofA

Steve Scala

TD Cowen

Hold

-8.36%

Downside

Reiterated

08/07/25

TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)

Geoff Meacham

Citi

Sell

-31.27%

Downside

Initiated

06/18/25

Novavax initiated with a Sell at CitiNovavax initiated with a Sell at Citi

Eric Joseph

J.P. Morgan

Sell

-19.82%

Downside

Reiterated

05/19/25

JPMorgan on Novavax (NVAX): Share Gain Likely Short-Lived Given Gap 2025 Commercial YearJPMorgan analyst Eric Joseph reiterated an Underweight rating and $7.00 price target on Novavax (NASDAQ: NVAX).

Mayank Mamtani

B. Riley Securities

$22

Buy

152.00%

Upside

Reiterated

12/19/24

Novavax's Strategic Partnerships and Pipeline Developments Drive Buy Rating with Promising Long-term Growth Potential

Roger Song

Jefferies

$31→$25

Buy

186.37%

Upside

Reiterated

10/16/24

Cautious Optimism for Novavax Amid Clinical Hold Challenges

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thomas Shrader

BTIG

$19

Buy

117.64%

Upside

Reiterated

09/02/25

Optimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy Rating

Sean Lee CFA

H.C. Wainwright

$10

Buy

14.55%

Upside

Initiated

08/28/25

Novavax assumed with a Buy at H.C. WainwrightNovavax assumed with a Buy at H.C. Wainwright

Alec Stranahan

Bank of America Securities

$9→$7

Sell

-19.82%

Downside

Downgraded

08/20/25

Novavax downgraded to Underperform from Neutral at BofANovavax downgraded to Underperform from Neutral at BofA

Steve Scala

TD Cowen

Hold

-8.36%

Downside

Reiterated

08/07/25

TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)

Geoff Meacham

Citi

Sell

-31.27%

Downside

Initiated

06/18/25

Novavax initiated with a Sell at CitiNovavax initiated with a Sell at Citi

Eric Joseph

J.P. Morgan

Sell

-19.82%

Downside

Reiterated

05/19/25

JPMorgan on Novavax (NVAX): Share Gain Likely Short-Lived Given Gap 2025 Commercial YearJPMorgan analyst Eric Joseph reiterated an Underweight rating and $7.00 price target on Novavax (NASDAQ: NVAX).

Mayank Mamtani

B. Riley Securities

$22

Buy

152.00%

Upside

Reiterated

12/19/24

Novavax's Strategic Partnerships and Pipeline Developments Drive Buy Rating with Promising Long-term Growth Potential

Roger Song

Jefferies

$31→$25

Buy

186.37%

Upside

Reiterated

10/16/24

Cautious Optimism for Novavax Amid Clinical Hold Challenges

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novavax

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

+1.07%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +1.07% per trade.

3 Months

xxx

Success Rate

10/11 ratings generated profit

Average Return

+24.75%

downgraded a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 90.91% of your transactions generating a profit, with an average return of +24.75% per trade.

1 Year

Alec StranahanBank of America Securities

Success Rate

7/11 ratings generated profit

Average Return

+16.84%

downgraded a sell rating last month

Copying Alec Stranahan's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +16.84% per trade.

2 Years

xxx

Success Rate

7/11 ratings generated profit

Average Return

+9.55%

downgraded a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +9.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A3S Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0A3S has received 2 Buy Ratings, 16 Hold Ratings, and 1 Sell Ratings. 0A3S average Analyst price target in the past 3 months is 11.00.

Each month's total comprises the sum of three months' worth of ratings.

0A3S Financial Forecast

0A3S Earnings Forecast

Next quarter’s earnings estimate for 0A3S is -$0.49 with a range of -$1.03 to -$0.19. The previous quarter’s EPS was $0.62. 0A3S beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year 0A3S has Outperformed its overall industry.

0A3S Sales Forecast

Next quarter’s sales forecast for 0A3S is $65.94M with a range of $32.55M to $127.59M. The previous quarter’s sales results were $239.24M. 0A3S beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.43% of the time in the same period. In the last calendar year 0A3S has Outperformed its overall industry.

0A3S Stock Forecast FAQ

What is GB:0A3S’s average 12-month price target, according to analysts?

Based on analyst ratings, Novavax’s 12-month average price target is 11.00.

What is GB:0A3S’s upside potential, based on the analysts’ average price target?

Novavax has 26.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novavax a Buy, Sell or Hold?

Novavax has a consensus rating of Hold, which is based on 2 buy ratings, 1 hold ratings and 1 sell ratings.

What is Novavax’s share price target?

The average share price target for Novavax is 11.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $19.00 ,and the lowest forecast is $7.00. The average share price target represents 26.00% Increase from the current price of $8.73.

What do analysts say about Novavax?

Novavax’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Novavax?

To buy shares of GB:0A3S, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novavax (0A3S) Share Forecast & Price Target

0A3S Analyst Ratings

0A3S Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novavax

0A3S Analyst Recommendation Trends

0A3S Financial Forecast

0A3S Earnings Forecast

0A3S Sales Forecast

0A3S Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts